Table 1.
Patient information
| Sample ID | Age | Sex | ISCL stage | B stage | CTCL subtype | Clinically abnormal phenotype | % CD4+CD26− | Abs. abn.∗ (/μL) | Treatment |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 81 | M | IVA | B2 | SS | CD3dim+ CD4+ CD7− CD26− CD2+ CD8− CD10− CD5+ | 87.8 | 1818.3 | ECP, ACIT |
| P2 | 76 | M | IIB | B1 | MF | CD3dim+ CD4+ CD7− CD26− CD8− CD5+ CD2+ | 37.4 | 1774.6 | ECP, BEX |
| P3 | 72 | F | IVA | B2 | SS | CD3+ CD4+ CD7Var+ CD26− CD8− CD2+ CD25− | 82.6 | 2799.6 | ECP, BEX, IFN-α |
| P4 | 79 | M | IA | B1 | MF | CD3dim+ CD4+ CD7− CD26− CD2+ | 61.2 | 964.5 | ECP, BEX |
| P5 | 56 | M | IVA | B2 | SS | CD3+ CD4+ CD7+CD26− CD2dim+ CD8− CD5+ CD25− | 60.1 | 973.6 | ECP, BEX |
| P6 | 85 | M | IVA | B2 | SS | CD3+ CD4+ CD7dim/− CD26− CD2Var+ CD8− CD5+ | 74.1 | 1387.2 | ECP, BEX |
| P7 | 78 | F | IVA | B2 | SS | CD3+CD4+CD7−CD26−CD5+CD8− | 42.3 | 802.0 | ECP, BEX, VRS |
| P8 | 74 | F | IVA | B2 | SS | CD3+ CD4+ CD7+CD26−CD8− | 89.0 | 979.0 | Moga |
| P9 | 68 | F | IVA | B1 | SS | CD3dim+ CD4dim+CD7− CD26dim/− CD2dim+CD8− CD10− CD5dim+ CD25− | 51.9 | 356.2 | ECP, BEX, IFN-α, IFN-γ |
| P10 | 70 | M | IIB | B1 | MF | CD3+ CD4+ CD7−/+ CD26− CD5dim+ | 44.8 | 503.9 | ECP, BEX |
| P11 | 76 | M | IIB | B1 | MF | CD3dim+ CD4dim+ CD7− CD26− CD5+ | 58.0 | 580.0 | ECP, BEX, IFN-α |
ISCL stage and B stage are at diagnosis, and blood counts and treatments are at the time of sequencing.
Abs. abn., absolute numbers of abnormal cells; ACIT, acitretin; BEX, bexarotene; ECP, extracorporeal photopheresis; IFN-α, interferon-α; ISCL, International Society for Cutaneous Lymphomas; Lymph, lymphocytes; Moga, mogamulizumab; VRS, Vorinostat; WBC, white blood cell.
∗
Abs. abn. = (% CD4+CD26− × % lymph.)/10 000 × WBC × 1000.